Immune tolerance induction with antihaemophilia factor (human) in poor prognosis patients with haemophilia A
- 3 February 2021
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 27 (3), E393-E397
- https://doi.org/10.1111/hae.14175
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The changing face of immune tolerance induction in haemophilia A with the advent of emicizumabHaemophilia, 2019
- Inhibitors: A Need for Eradication?Acta Haematologica, 2019
- Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrateHaemophilia, 2019
- Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patientsEuropean Journal of Haematology, 2018
- The importance of inhibitor eradication in clinically complicated hemophilia A patientsExpert Review of Hematology, 2018
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsThe New England Journal of Medicine, 2017
- Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrateHaemophilia, 2013
- The principal results of the International Immune Tolerance Study: a randomized dose comparisonBlood, 2012
- The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experienceJournal of Thrombosis and Haemostasis, 2011